Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5 : a study from the Acute Leukemia Working Party of the EBMT
| Autor: | Arnold Ganser, Jan J. Cornelissen, Xavier Poiré, Ibrahim Yakoub-Agha, Mauricette Michallet, Liisa Volin, Didier Blaise, Edouard Forcade, Jürgen Finke, Jordi Esteve, Mohamad Mohty, Arnon Nagler, Myriam Labopin, Carlos Richard Espiga, Johan Maertens, Emmanuelle Polge |
|---|---|
| Přispěvatelé: | HUS Comprehensive Cancer Center, Department of Oncology, Hematologian yksikkö, Hematology |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Acute Myeloid Leukemia
Adult Oncology medicine.medical_specialty Allogeneic transplantation Monosomy 5 COMPLEX ABERRANT KARYOTYPE 3122 Cancers Article 03 medical and health sciences Monosomy 0302 clinical medicine YOUNGER ADULTS Internal medicine Complex Karyotype PROGNOSTIC-SIGNIFICANCE medicine Humans Transplantation Homologous MARROW-TRANSPLANTATION Survival rate RISK MYELODYSPLASTIC SYNDROMES Chromosome 7 (human) Acute leukemia EUROPEAN GROUP Science & Technology business.industry Hematopoietic Stem Cell Transplantation Myeloid leukemia Hematology 1ST COMPLETE REMISSION Prognosis TP53 MUTATIONS 3. Good health Transplantation LENALIDOMIDE MAINTENANCE Leukemia Myeloid Acute Karyotyping business Life Sciences & Biomedicine 030215 immunology POSTREMISSION THERAPY |
| Zdroj: | Haematologica, 105(2), 414-423. Ferrata Storti Foundation Haematologica |
| ISSN: | 0390-6078 |
| Popis: | Deletion 5q or monosomy 5 (-5/5q-) in acute myeloid leukemia (AML) is a common high-risk feature that is referred to allogeneic stem cell transplantation. However, -5/5q- is frequently associated with other high-risk cytogenetic aberrations such as complex karyotype, monosomal karyotype, monosomy 7 (-7), or 17p abnormalities (abn (17p)), the significance of which is unknown. In order to address this question, we studied adult patients with AML harboring -5/5q- having their first allogeneic transplantation between 2000 and 2015. Five hundred and one patients with -5/5q- have been analyzed. Three hundred and thirty-eight patients (67%) were in first remission and 142 (28%) had an active disease at time of allogeneic transplantation. The 2-year probabilities of overall survival and leukemia-free survival were 27% and 20%, respectively. The 2-year probability of treatment-related mortality was 20%. We identified four different cytogenetic groups according to additional abnormalities with prognostic impact: -5/5q- without complex karyotype, monosomal karyotype or abn(17p), -5/5q- within a complex karyotype, -5/5q- within a monosomal karyotype and the combination of -5/5q- with abn(17p). In multivariate analysis, factors associated with worse overall survival and leukemia-free survival across the four groups were active disease, age, monosomal karyotype, and abn(17p). The presence of -5/5q- without monosomal karyotype or abn(17p) was associated with a significantly better survival rate while -5/5q- in conjunction with monosomal karyotype or abn(17p) translated into a worse outcome. The patients harboring the combination of -5/5q- with abn(17p) showed very limited benefit from allogeneic transplantation. ispartof: HAEMATOLOGICA vol:105 issue:2 pages:414-423 ispartof: location:Italy status: published |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|